Concepts & Frameworks

Allostatic load is the cumulative physiological cost of adapting to chronic stressors, representing wear and tear on regulatory systems that maintain homeostasis through continuous adjustment—a process termed allostasis. The concept was developed by Bruce McEwen and Eliot Stellar in 1993 and operationalised in epidemiology as a composite score across neuroendocrine (e.g. cortisol, DHEA-S), cardiovascular, metabolic, and immune biomarkers. Higher allostatic load predicts all-cause mortality, cardiovascular disease, cognitive decline, and accelerated biological ageing, and mediates socioeconomic disparities in health. In longevity research, it provides a framework for understanding how cumulative psychosocial and environmental stress translates into measurable organ-system dysregulation.

Antagonistic pleiotropy, formulated by evolutionary biologist George C. Williams in 1957, holds that genes selected for benefits early in life can cause harm later, after reproduction has occurred. Because selection pressure weakens with age, such alleles persist despite late-life costs. The hypothesis is a foundational explanation for why aging evolved and remains a leading evolutionary framework alongside mutation accumulation and disposable soma theory.

Biological age is an estimate of how old a person's body appears to be based on physiological and molecular markers, rather than the calendar. It can be derived from blood biomarkers (e.g. PhenoAge), DNA methylation patterns (epigenetic clocks), grip strength, gait speed or organ-specific proteomic signatures. Although widely used in longevity research, no single biological-age measure is yet endorsed by regulators as a clinical endpoint, and validation varies strongly between methods.

A caloric restriction mimetic (CR mimetic) is a compound that reproduces some molecular and physiological effects of caloric restriction — including AMPK activation, mTORC1 inhibition, sirtuin activation, reduced insulin/IGF-1 signalling, enhanced autophagy and favourable shifts in metabolic biomarkers — without requiring a sustained reduction in food intake. The concept was formalised by Ingram and colleagues in 1998. Leading candidates include rapamycin (mTOR inhibitor), metformin (AMPK activator), resveratrol (putative SIRT1 activator), NAD+ precursors (NMN, NR) and acarbose. Evidence for lifespan extension in mice is established for rapamycin and acarbose under ITP conditions; translation to humans remains an open research question, and no CR mimetic has demonstrated robust healthspan extension in a powered randomised human trial.

A centenarian is a person who has reached the age of 100 years or more. Centenarians are a key research population in longevity science because they typically delay or escape major age-related diseases. Studies such as the New England Centenarian Study and Japan's Okinawa Centenarian Study examine genetic, lifestyle, and environmental factors associated with exceptional human lifespan and healthspan.

Chronological age is the time elapsed since a person's birth, usually measured in years. It is the standard reference variable in demography, medicine and epidemiology and remains one of the strongest single predictors of mortality and many age-associated conditions. Unlike biological age, chronological age does not capture variation in physiological decline between individuals; two people of the same chronological age may differ markedly in functional capacity, disease risk and remaining healthspan, and depending on cohort and endpoint other measures can match or exceed its predictive value.

Compression of morbidity is a concept introduced by James Fries in 1980 describing a scenario in which the onset of chronic disease and disability is postponed faster than the increase in lifespan, so that severe illness is concentrated into a shorter period at the end of life. It is a guiding goal of geroscience and healthspan-oriented medicine. Empirical evidence is mixed: in some populations morbidity has compressed, in others it has expanded as lifespan rose.

The disposable soma theory, proposed by Thomas Kirkwood in 1977, posits that organisms allocate finite metabolic resources between somatic maintenance and reproduction. Because natural selection favors reproductive success, the body invests only enough in repair to survive likely environmental hazards, leaving residual damage that accumulates as aging. The theory remains influential in evolutionary biogerontology and underlies modern thinking on caloric restriction and trade-offs.

Frailty is a clinical state of increased vulnerability to stressors resulting from accumulated deficits across multiple physiological systems, leading to diminished reserve and resilience. Two complementary operationalisations dominate the literature: the phenotypic frailty model of Fried and colleagues (2001, Cardiovascular Health Study), which defines frailty by at least three of five criteria (unintentional weight loss, exhaustion, low grip strength, slow walking speed, low physical activity); and the Frailty Index of Mitnitski and Rockwood, which counts the proportion of health deficits present across 30–70 items (symptoms, signs, diagnoses, laboratory values). Both predict adverse outcomes—falls, hospitalisation, disability, and mortality—independently of chronological age, and frailty prevalence rises sharply after age 80. In geroscience, it is a key functional outcome for evaluating senolytic, senostatic, and other geroprotective interventions.

The free radical theory of aging, proposed by Denham Harman in 1956, originally attributed aging to cumulative cellular damage from oxygen-derived free radicals, drawing on rate-of-living and oxygen-toxicity reasoning. Harman's 1972 update, the mitochondrial free radical theory of aging (MFRTA), specifically implicated mitochondrial ROS and mtDNA as the central drivers. While oxidative damage is undeniably involved, large antioxidant trials largely failed, and the theory is now considered partial. Modern frameworks integrate it with mitochondrial dysfunction and redox signaling.

Gerontology is the scientific study of aging across biological, psychological, and social dimensions. Established as a formal discipline in the early 20th century, with Ilya Mechnikov coining the term in 1903, it encompasses biogerontology, social gerontology, and geriatric medicine. It remains the broader umbrella field within which geroscience focuses specifically on molecular and cellular mechanisms relevant to disease prevention.

Geroscience is an interdisciplinary field that investigates the biological mechanisms of aging and their causal links to chronic disease. Coined around 2007 by researchers at the Buck Institute and formalized by the NIH-led Geroscience Interest Group, it rests on the premise that targeting aging itself can simultaneously delay multiple age-related conditions. It now underpins translational efforts like the TAME trial.

Gompertz law, formulated by the British actuary Benjamin Gompertz in 1825, describes the empirical observation that human mortality risk increases exponentially with adult age: specifically, the force of mortality (hazard rate) approximately doubles every 8 years in most high-income populations. Mathematically, the instantaneous mortality rate is expressed as μ(t) = a·e^(bt), where a is the baseline mortality rate and b is the age-dependent acceleration. The law holds across most of adult life in humans and many other species, but mortality deceleration or plateaus observed at very old ages suggest it is not universal beyond the oldest cohorts. Gompertz dynamics are central to actuarial science, epidemiology, and the theoretical biology of ageing.

A hazard ratio is the ratio of the instantaneous event rate in one group to that in a reference group at any given moment during follow-up, derived from a Cox proportional-hazards regression model. An HR of 0.75 means the treated group experiences the event at 75% of the rate of controls throughout follow-up, not that overall risk is reduced by 25% at a fixed time point — a common misreading. The proportional-hazards assumption requires that this ratio remain constant over time; violations (e.g., time-varying drug effects) must be tested, and when present, time-restricted or parametric models are more appropriate. In longevity and survival studies the HR is the dominant effect measure, but its magnitude depends on baseline hazard and follow-up length, limiting direct comparisons across trials.

Healthspan is the period of life spent in good health, free from serious chronic disease and major functional impairment. It is conceptually distinct from lifespan, which counts total years lived. In longevity research healthspan is increasingly preferred as an outcome because the goal is to compress the years of frailty and disease at the end of life. Operational definitions vary and may use disease-free survival, disability indices or composite biomarker scores.

Heritability of lifespan is the proportion of variance in age at death attributable to additive genetic differences among individuals in a defined population. Classic twin-study estimates placed narrow-sense heritability at roughly 20–30% (Herskind et al. 1996); large-scale genomic analyses and a 2018 study in Genetics (Ruby et al.) using genealogical databases suggested even lower heritability once marital assortment is properly accounted for, with some estimates falling below 10% for lifespan itself. More recent analyses (Shenhar et al. 2026, Science) that better account for confounding factors place the intrinsic heritability of human life span at approximately 50%, suggesting earlier estimates may have been deflated by failure to separate intrinsic from extrinsic mortality. Even at the higher end, modifiable factors — lifestyle, environment, stochastic events — account for a substantial portion of variance. Specific genetic variants such as APOE ε4 and FOXO3A show replicated associations with mortality risk and exceptional longevity respectively, even if their individual effect sizes are modest.

The Kaplan-Meier estimator is a nonparametric method for estimating the survival function S(t) — the probability of surviving beyond a given time t — from censored time-to-event data. At each event time, the estimate is updated as the ratio of subjects remaining at risk minus those who experienced the event, multiplied forward as a product-limit. The resulting step function graphically displays survival over follow-up and allows group comparisons via the log-rank test. Key assumptions include that censoring is non-informative (i.e., subjects who leave the study do not systematically differ in prognosis) and that survival probability is independent across individuals. The median survival — where the curve crosses 50% — is the standard summary statistic; mean survival is rarely used because it requires the curve to reach zero.

Lifespan is the total length of time an organism lives, from birth to death, typically expressed in years for humans. In population terms it is summarised by life expectancy at birth or at a given age. Maximum lifespan refers to the longest documented age reached within a species; for humans this is around 122 years. Lifespan is influenced by genetics, environment, behaviour and access to medical care, and is a classic outcome in longevity research.

Longevity escape velocity describes a hypothetical threshold at which medical advances extend remaining life expectancy by more than one year per calendar year, effectively outrunning aging. Popularized by biogerontologist Aubrey de Grey in the early 2000s, it remains a speculative concept rather than an empirically validated milestone. Mainstream geroscience treats it as an aspirational framing rather than a near-term forecast.

Mendelian randomization (MR) uses germline genetic variants — typically single-nucleotide polymorphisms associated with an exposure in a genome-wide association study — as instrumental variables to estimate the causal effect of that exposure on an outcome, exploiting the random allocation of alleles at conception as a natural experiment. The method relies on three core assumptions: the instrument is robustly associated with the exposure (relevance), affects the outcome only through that exposure (exclusion restriction), and is independent of confounders (independence). Violations — through pleiotropy, population stratification, or weak instruments — are major pitfalls; sensitivity analyses including MR-Egger, weighted-median, and CAUSE help detect and partially correct for horizontal pleiotropy. In longevity research, MR has been widely used to test causal links between biomarkers such as LDL-C, CRP, IGF-1, or BMI and lifespan outcomes without requiring decades-long randomized trials.

Mortality doubling time (MDT) is the number of years it takes for age-specific mortality risk to double, derived directly from the Gompertz exponent b as MDT = ln(2)/b. In contemporary high-income populations, the MDT for all-cause mortality is approximately 7–8 years in mid-adulthood, meaning a 50-year-old's annual risk of dying is roughly twice that of a 42–43-year-old. MDT is a compact summary of the rate of actuarial ageing and is used comparatively across species (where it varies from months in short-lived organisms to decades in naked mole-rats and humans) and across population subgroups, enabling detection of interventions that alter ageing rate rather than merely shifting baseline mortality.

Multimorbidity is defined as the co-occurrence of two or more chronic conditions within the same person, without designating a primary or index disease — a distinction from the related but person-centred concept of comorbidity. Its prevalence rises sharply with age: roughly 50% of adults over 65 in high-income countries live with three or more chronic conditions. Multimorbidity is strongly associated with polypharmacy, functional decline, reduced quality of life, greater healthcare utilisation and higher mortality, and it challenges single-disease clinical guidelines that were developed in trial populations that often excluded it. In geroscience, multimorbidity is both a key outcome of biological aging and a prime motivation for targeting upstream aging processes rather than individual diseases sequentially.

Negligible senescence describes organisms that show no measurable functional decline, increase in mortality risk, or loss of reproductive capacity with chronological age. The term was coined by biogerontologist Caleb Finch in his 1990 book 'Longevity, Senescence, and the Genome' to characterize species such as certain rockfish, certain tortoises, and hydra. Naked mole-rats, often cited in this context, exhibit extremely slow but not strictly negligible senescence and became associated with this discussion through later work (e.g., Buffenstein 2008 onward). Negligible senescence is studied as a comparative biology benchmark for understanding why most mammals, including humans, do age.

The oldest-old is a demographic and gerontological term for individuals aged 85 and above, the fastest-growing segment of most high-income country populations. This group shows heterogeneous functional and cognitive trajectories; a substantial minority maintains high functional capacity into the late eighties and beyond, a phenomenon sometimes termed successful aging. Compared with younger old adults (65–84), the oldest-old display distinct epidemiology: traditional cardiovascular risk factors such as hypertension and elevated LDL-C lose predictive power, while markers of physical function, nutritional status, and resilience become stronger mortality predictors. Studying this group is methodologically complicated by survival bias — those who reach 85 are a selected population — which may inflate associations between traits observed at that age and longevity.

Polypharmacy is conventionally defined as the concurrent use of five or more medications by one patient, though thresholds vary by definition (some use ≥4, hyperpolypharmacy typically ≥10); it must be distinguished from appropriate polypharmacy, in which multiple drugs are each evidence-based for the individual's conditions. Prevalence increases sharply with age and multimorbidity — over 40% of adults aged 65 and older in many high-income countries take five or more drugs. The clinical risks include drug-drug interactions, additive adverse effects, prescribing cascades (where a drug side effect is treated with another drug), impaired adherence, falls, cognitive impairment and hospitalisation. Deprescribing — the structured reduction of medications that lack net benefit — is an emerging discipline in geriatric and longevity medicine, supported by a growing evidence base for specific drug classes including proton pump inhibitors, benzodiazepines and anticholinergics in older adults.

The reliability theory of aging, advanced by Leonid and Natalia Gavrilov in the early 1990s, applies engineering reliability mathematics to biological systems. It models organisms as redundant networks of components that fail stochastically; aging arises as redundancy depletes, producing the observed Gompertz mortality curve. The theory elegantly explains late-life mortality plateaus and provides a quantitative bridge between molecular damage and population-level survival data.

A supercentenarian is a person verified to have reached the age of 110 years or more. The 110+ threshold and term were popularized chiefly by L. Stephen Coles, founder of the Gerontology Research Group, with demographer James Vaupel contributing complementary validation work through MPIDR and the International Database on Longevity. The cohort numbers only a few hundred globally at any time and is studied for genetic resilience, late-life morbidity compression, and as a benchmark against unverified age claims.